Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-017315
Filing Date
2023-05-15
Accepted
2023-05-15 16:06:27
Documents
86
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1389832
2 ex31-1.htm EX-31.1 10957
3 ex31-2.htm EX-31.2 11066
4 ex32-1.htm EX-32.1 8107
  Complete submission text file 0001493152-23-017315.txt   8547030

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE qlgn-20230331.xsd EX-101.SCH 69617
6 XBRL CALCULATION FILE qlgn-20230331_cal.xml EX-101.CAL 77802
7 XBRL DEFINITION FILE qlgn-20230331_def.xml EX-101.DEF 344351
8 XBRL LABEL FILE qlgn-20230331_lab.xml EX-101.LAB 547736
9 XBRL PRESENTATION FILE qlgn-20230331_pre.xml EX-101.PRE 467592
80 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1425662
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37428 | Film No.: 23922087
SIC: 2834 Pharmaceutical Preparations